MUMBAI, India, June 19, 2013 /PRNewswire/ -- Bharat Book Bureau presents Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies ( http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/innovative-drug-delivery-systems-novel-product-and-formulation-technology-licensing-opportunities-for-generic-pharmaceutical-companies.html) There are more than 1400 sustained or controlled release drugs approved all over the world. Revenues within the global generics market reached an estimated value of $265 billion in 2012, showing a growth of 9.3% throughout the year. The oral drug delivery market remains the largest slice of the overall drug delivery market, with more than 52% of market share. It is presently valued at $49 billion and is expected to reach over $90 billion by 2016, at a CAGR of 11%. Global injectable drug delivery market is expected to be worth $29b by 2015. The oral drug delivery market remains the largest slice of the overall drug delivery market, with more than 52% of market share. (Logo: http://photos.prnewswire.com/prnh/20130128/590935 ) Novel drug delivery systems (NDDS) offer many more advantages, which include improved therapy by increasing the efficacy and duration of drug activity, increased patient compliance through decreased dosing frequency and convenient routes of administration, and improved targeting for a specific site to reduce unwanted side effects. The challenge for both drug and drug delivery companies is to deliver both existing and emerging drug technologies in a manner that improves the current benefits enjoyed by the patients. The generic market with reference to the innovative molecule (NCE) has become very competitive as several companies have already filed ANDA's for potential generic drugs in the near term. The study of the novel drug delivery companies and their formulation technologies will provide the potential value added opportunity in the generic field in terms of the patient's compliance or bioavailability enhancement.